Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life: 1-year results from the FRANCE ABSORB registry
Guillaume Cayla, René Koning, Jean Fajadet, Joel Sainsous, Didier Carrié, Simon Elhadad, Francois Tarragano, Thierry Lefévre, Sylvain Ranc, Said Ghostine, Philippe Garot, Frédéric Marco, Luc Maillard, Pascal Motreff, Hervé Le Breton, FRANCE ABSORB investigators, Guillaume Cayla, René Koning, Jean Fajadet, Joel Sainsous, Didier Carrié, Simon Elhadad, Francois Tarragano, Thierry Lefévre, Sylvain Ranc, Said Ghostine, Philippe Garot, Frédéric Marco, Luc Maillard, Pascal Motreff, Hervé Le Breton, FRANCE ABSORB investigators
Abstract
Background: Several randomized studies have shown that bioresorbable vascular scaffold (BVS) technology is associated with an increased risk of stent thrombosis.
Aim: This study aimed to assess the rates of adverse outcomes at 1 year in patients treated with the Absorb BVS (Abbott Vascular, Santa Clara, CA, USA), using data from a large nationwide prospective multicentre registry (FRANCE ABSORB).
Methods: All patients receiving the Absorb BVS in France were included prospectively in the study. Predilatation, optimal sizing and postdilatation were recommended systematically. The primary endpoint was a composite of cardiovascular death, myocardial infarction and target lesion revascularization at 1 year. Secondary endpoints were scaffold thrombosis and target vessel revascularization at 1 year.
Results: A total of 2072 patients at 86 centres were included: mean age 55±11 years; 80% men. The indication was acute coronary syndrome (ACS) in 49% of cases. Predilatation and postdilatation were done in 93% and 83% of lesions, respectively. At 1 year, the primary endpoint occurred in 3.9% of patients, the rate of scaffold thrombosis was 1.5% and the rate of target vessel revascularization was 3.3%. In a multivariable analysis, diabetes and total Absorb BVS length>30mm were independently associated with the occurrence of the primary endpoint, whereas oral anticoagulation and total Absorb BVS length>30mm were independently associated with occurrence of scaffold thrombosis.
Conclusions: The Absorb BVS was implanted in a relatively young population, half of whom had ACS. Predilatation and postdilatation rates were high, and 1-year outcomes were acceptable.
Keywords: Acute coronary syndrome; Angioplastie coronaire; Bioresorbable scaffolds; Percutaneous coronary intervention; Stent bioresorbable; Syndrome coronaire aigu.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
Source: PubMed